全文获取类型
收费全文 | 996篇 |
免费 | 130篇 |
出版年
2021年 | 13篇 |
2020年 | 8篇 |
2018年 | 7篇 |
2016年 | 13篇 |
2015年 | 14篇 |
2014年 | 36篇 |
2013年 | 34篇 |
2012年 | 54篇 |
2011年 | 39篇 |
2010年 | 32篇 |
2009年 | 20篇 |
2008年 | 22篇 |
2007年 | 23篇 |
2006年 | 31篇 |
2005年 | 37篇 |
2004年 | 32篇 |
2003年 | 24篇 |
2002年 | 25篇 |
2001年 | 20篇 |
2000年 | 30篇 |
1999年 | 33篇 |
1998年 | 20篇 |
1997年 | 12篇 |
1996年 | 17篇 |
1995年 | 16篇 |
1994年 | 11篇 |
1993年 | 18篇 |
1992年 | 27篇 |
1991年 | 24篇 |
1990年 | 29篇 |
1989年 | 23篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 12篇 |
1985年 | 14篇 |
1984年 | 22篇 |
1983年 | 12篇 |
1982年 | 14篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1979年 | 11篇 |
1978年 | 12篇 |
1977年 | 9篇 |
1976年 | 15篇 |
1973年 | 11篇 |
1972年 | 13篇 |
1971年 | 7篇 |
1970年 | 9篇 |
1969年 | 11篇 |
1888年 | 7篇 |
排序方式: 共有1126条查询结果,搜索用时 343 毫秒
991.
Summary The role of antigen-reactive cell opsonization (ARCO) in a syngeneic tumor system and its effect on tumor progression was investigated. Thus, anti-tumor reactive T cells were prepared in vivo by immunization of normal SJL/J mice with mitomycin C-inactivated tumor cells of the syngeneic transplantable reticulum cell sarcoma (RCS) line LA-6. Dividing cells were subsequently labeled by injecting iodo-2-deoxyuridine (125IUdR) into the same animals 3 days later. Antigen-reactive cells (*ARC) present in the radiolabeled, nylon wool-fractionated spleen cell population taken from these mice on day 4 and injected IV into syngeneic SJL/J mice bearing LA-6 tumors were diverted to the liver and away from the spleen. The effect was maximal by 8 days following inoculation of tumor cells, and was specific inasmuch as 125IUdR-labeled cells prepared by immunization with allogeneic spleen or tumor cells which were not opsonized in day-8 LA-6 tumor-bearing mice. Opsonization of *ARC in day-8 LA-6 tumor-bearing mice was completely abrogated by either prior injection of heat-aggregated immunoglobulin into the mice or preincubation of the *ARC in solubilized tumor antigen before injection into tumor-bearing mice, demonstrating the involvement of Fc receptors in the host and antigen-specific receptors on the *ARC, respectively, in the opsonizing process. When anti-LA-6 reactive T cells were incubated in serum from LA-6 tumor-bearing mice and then injected IV into normal syngeneic SJL/J mice, a similar liver diversion was observed. Serum from cyclophosphamide-pretreated mice injected with LA-6 or serum from mice given mitomycin C-inactivated LA-6 cells did not cause opsonization of tumor-reactive T cells, while a mixture of these two sera did have some *ARC opsonizing activity. Further experiments with SJL/J mice bearing spontaneous RCS tumor indicate that tumor-reactive T cells are also opsonized in these mice. The above studies and others suggested that ARCO may play an important role in vivo in the survival of tumors.
Abbreviations used in this paper are: ARC, antigen-reactive cells; ARC, radiolabeled antigen-reactive cells; ARCO, antigen-reactive cell opsonization; LA-6 tumor line derived in our laboratory; L.I., localization index; PEG, polyethylene glycol; RCS, reticulum cell sarcoma; STA, soluble tumor antigen; TBS, tumor-bearer serum 相似文献
992.
993.
994.
995.
996.
A controlled double-blind study of the effect of dipyridamole was performed in 169 patients with established cerebral vascular disease. A dose of 400 mg. was used initially, given daily for an average of 14 months; the dose was then increased to 800 mg. daily for a further average period of 11 months. When the incidence of cerebral ischaemic episodes during treatment was compared in the drug-treated and placebo-treated groups no significant difference was found. 相似文献
997.
Scadoxus nutans (Friis & I. Björnstad) Friis & Nordal is described and illustrated; its habitat, distribution and conservation status are discussed. 相似文献
998.
999.
J C Sisson B Shapiro R J Hutchinson K R Zasadny S Mallette E E Mudgett D M Wieland 《Journal of nuclear biology and medicine (Turin, Italy : 1991)》1991,35(4):255-259
To find a treatment that may be effective against micrometastases of advanced, stage III or IV neuroblastoma, [125I]metaiodobenzylguanidine (125I-MIBG) was used in a phase I toxicity trial. In seven patients, thrombocytopenia was encountered with absorbed whole body doses of 85-135 rad from 125I-MIBG, but the dosimetry was imprecise in predicting bone marrow injury. Three patients survived for over one year, results that may indicate efficacy of 125I-MIBG therapy. 相似文献
1000.